PW Medtech Group Limited (HKG:1358)
Hong Kong · Delayed Price · Currency is HKD 1.020
+0.010 (0.99%)
At close: Mar 27, 2026
PW Medtech Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 823.51 | 768.9 | 675.08 | 536.83 | 271.4 | |
Revenue Growth (YoY) | 7.10% | 13.90% | 25.75% | 97.80% | 9.72% |
Cost of Revenue | 416.05 | 349.46 | 294.19 | 238 | 105.34 |
Gross Profit | 407.46 | 419.45 | 380.9 | 298.83 | 166.06 |
Selling, General & Admin | 268.86 | 240.88 | 195.11 | 189.57 | 123.09 |
Research & Development | 48.41 | 44.12 | 41.13 | 40.98 | 20.25 |
Other Operating Expenses | -28.65 | -39.55 | -34.48 | -29.89 | -24.35 |
Operating Expenses | 282.12 | 245.44 | 201.76 | 200.66 | 118.99 |
Operating Income | 125.34 | 174.01 | 179.14 | 98.17 | 47.07 |
Interest Expense | - | -0.37 | -0.15 | -0.46 | -0.61 |
Interest & Investment Income | - | 50.65 | 43.83 | 35.37 | 57.34 |
Currency Exchange Gain (Loss) | - | 7.5 | 3.49 | 30.47 | -40.88 |
Other Non Operating Income (Expenses) | 42.69 | - | - | - | - |
EBT Excluding Unusual Items | 168.03 | 231.78 | 226.3 | 163.54 | 62.92 |
Merger & Restructuring Charges | - | - | - | -4.8 | -3.92 |
Gain (Loss) on Sale of Assets | - | -0.11 | -7.14 | -0.01 | 731.79 |
Asset Writedown | -3.04 | -1.18 | -0.06 | -0.25 | -52.59 |
Legal Settlements | - | -0.73 | -0.73 | -0.73 | -0.73 |
Other Unusual Items | - | - | 12.7 | - | - |
Pretax Income | 164.99 | 229.75 | 231.07 | 157.75 | 737.46 |
Income Tax Expense | 29.74 | 37.23 | 26.04 | 28.88 | -1.65 |
Earnings From Continuing Operations | 135.25 | 192.52 | 205.02 | 128.87 | 739.12 |
Net Income to Company | 135.25 | 192.52 | 205.02 | 128.87 | 739.12 |
Minority Interest in Earnings | -40.88 | -41.74 | -51.84 | -22.83 | 0 |
Net Income | 94.37 | 150.78 | 153.18 | 106.04 | 739.12 |
Net Income to Common | 94.37 | 150.78 | 153.18 | 106.04 | 739.12 |
Net Income Growth | -37.41% | -1.57% | 44.46% | -85.65% | 16.98% |
Shares Outstanding (Basic) | 1,510 | 1,543 | 1,566 | 1,566 | 1,569 |
Shares Outstanding (Diluted) | 1,510 | 1,543 | 1,566 | 1,566 | 1,569 |
Shares Change (YoY) | -2.17% | -1.42% | -0.03% | -0.20% | -0.00% |
EPS (Basic) | 0.06 | 0.10 | 0.10 | 0.07 | 0.47 |
EPS (Diluted) | 0.06 | 0.10 | 0.10 | 0.07 | 0.47 |
EPS Growth | -36.02% | -0.11% | 44.46% | -85.63% | 16.99% |
Free Cash Flow | - | 261.93 | 163.73 | 216.77 | 25.92 |
Free Cash Flow Per Share | - | 0.17 | 0.10 | 0.14 | 0.02 |
Dividend Per Share | - | 0.092 | 0.089 | - | - |
Dividend Growth | - | 3.00% | - | - | - |
Gross Margin | 49.48% | 54.55% | 56.42% | 55.66% | 61.19% |
Operating Margin | 15.22% | 22.63% | 26.54% | 18.29% | 17.34% |
Profit Margin | 11.46% | 19.61% | 22.69% | 19.75% | 272.34% |
Free Cash Flow Margin | - | 34.06% | 24.25% | 40.38% | 9.55% |
EBITDA | 240.62 | 289.28 | 276.11 | 175.49 | 77.98 |
EBITDA Margin | 29.22% | 37.62% | 40.90% | 32.69% | 28.73% |
D&A For EBITDA | 115.28 | 115.28 | 96.97 | 77.32 | 30.91 |
EBIT | 125.34 | 174.01 | 179.14 | 98.17 | 47.07 |
EBIT Margin | 15.22% | 22.63% | 26.54% | 18.29% | 17.34% |
Effective Tax Rate | 18.03% | 16.20% | 11.27% | 18.31% | - |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.